Assessment of Acceptability and Initial Effectiveness of a Unified Protocol Prevention Program to Train Emotional Regulation Skills in Female Nursing Professionals during the COVID-19 PandemicRandomized Controlled Trial Published on 2022-05-072022-10-04 Journal: International Journal of Environmental Research an [Category] COVID19(2023년), SARS, 임상, [키워드] acceptability Anxiety assessment Burnout caused control group COVID-19 COVID-19 pandemic distress Effectiveness emotion regulation skills emotional Emotional exhaustion evaluate evaluated event favor female hospital increases in Interaction Intervention Nursing nursing professionals pandemic participant pilot study post-intervention prevention professional professionals Program protocol Quality of life Randomized reduce Regulation Satisfaction shown skill Spanish statistically significant statistically significant reduction stressful situations Symptom treatment group unified protocol. variable women [DOI] 10.3390/ijerph19095715 PMC 바로가기 [Article Type] Randomized Controlled Trial
Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study한국에서 중등도 SARs-CoV-2 환자에 대한 3세대 세팔로스포린, 아지트로마이신 및 항바이러스제 병용 치료: 후향적 코호트 연구Article Published on 2022-05-042022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 치료제, [키워드] adjust administration adverse event Analysis analyzed Antibiotics antiviral agent Antiviral agents association Azithromycin baseline characteristics cephalosporin Clinical outcome Cohort cohorts Combined combined treatment conducted confounding factors COVID-19 COVID-19 patient Cox regression analysis Cox regression method death Efficacy and safety Endpoint endpoints Evidence groups hazard ratio hazard ratios Hospital stay Hydroxychloroquine inclusion criteria Kaplan-Meier Kaplan-Meier curve Kaplan-Meier curves laboratory-confirmed Lopinavir Lopinavir/ritonavir low-dose mild to moderate Mild to moderate COVID-19 moderate Moderate COVID-19 moderate COVID-19 patients no significant difference no significant differences not significant Patient performed Prevent Propensity score propensity score matching PSM retrospective cohort study Ritonavir SARS-CoV-2 SARS-CoV-2 patient SARS-CoV-2 patients significant differences South South Korea Standard standard supportive care statistical significance Supportive treatment symptom resolution Time to symptom resolution Treatment treatment arm treatment group viral clearance were used [DOI] 10.1371/journal.pone.0267645 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study건강한 성인에서 AS03 보조제 SARS-CoV-2 재조합 단백질 백신(CoV2 preS dTM)의 안전성 및 면역원성: 2상, 무작위, 용량 찾기, 다기관 연구의 중간 결과Clinical Trial Published on 2022-05-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 95% CI abstinence adjuvants Adults adverse event adverse events Adverse reaction Adverse reactions age All participant All participants antibody Antibody titre Antigen AS03 assessments assigned authority baseline booster vaccination candidate vaccine Chemotherapy childbearing potential clinical development Clinical research clinical trial Cohort Contraception COVID-19 vaccine D614G variant development dose effective Endpoint enrolled evaluated expected fixed Frequency geometric mean geometric mean titre GMT GMT ratio GMTs groups healthy High dose High-dose high-dose group Immunocompromised immunogenicity increase in increased risk injection injection site Injections intensity interim results investigator investigators involved Laboratory lactating low dose low-dose medical condition Medical conditions medium medium dose Mild mild to moderate moderate multicentre Neutralising Antibodies neutralising antibody neutralising antibody titre neutralising antibody titres occurred Older Older adults Organ transplant outcome outcome assessor outcome assessors parallel-group participant Participants Phase 2 Phase 3 positive prefusion pregnant primary immunogenicity progression proportion Protein protocol provided pseudovirus neutralisation assay randomised Randomly reactogenicity receive Registered reported Research research and development responses robust Safety safety analysis safety endpoints safety profile Sanofi Pasteur SARS-CoV-2 second dose second vaccination selected Serious Adverse Event Serious Adverse Events serodiagnostic Seven severe COVID-19 Stratification study period supported systemic test result titre titres Treatment treatment group treatment groups Trial USA vaccination Vaccine was done were excluded were measured yes or no [DOI] 10.1016/S1473-3099(21)00764-7 PMC 바로가기 [Article Type] Clinical Trial
Light acupuncture and five-element music therapy for nurses’ mental health and well-being during and post-COVID-19: protocol for a randomised cross-over feasibility study코로나19 기간 및 이후 간호사의 정신 건강과 웰빙을 위한 가벼운 침술 및 5요소 음악 요법: 무작위 교차 타당성 연구를 위한 프로토콜Article Published on 2022-04-292022-09-11 Journal: BMJ Open [Category] 임상, [키워드] affected Analysis Anxiety asked assessments Blinding clinical clinical trial Combination Community Complete COVID-19 pandemic cross-over Depression depression & dissemination Edith eligible engage Ethical approval Ethics ethics committee evaluate Evidence feasibility Feasibility study form Health healthcare professionals hospital Human Impact IMPROVE include Intention International Intervention Laser Laser therapy LIGHT Local management mental health mood disorders music therapy National New Nurse online questionnaire online questionnaires PAIN MANAGEMENT participant peer-reviewed performed Primary outcome profession protocol Quality of life randomised recruited registration number required Research Ethics research findings resulting secondary outcome Secondary outcomes Studio therapeutic effect therapy Treatment treatment group Trial Two-arm university Well-being [DOI] 10.1136/bmjopen-2021-057106 PMC 바로가기 [Article Type] Article
A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19Clinical Trial Published on 2022-04-082022-10-05 Journal: Med (New York, N.Y.) [Category] 바이오마커, 임상, [키워드] accelerated acute respiratory distress acute respiratory distress syndrome addition alpha-1 antitrypsin Anti-inflammatory ARDS biochemically changes in circulating Clinical outcome clinical trial Concentration coronavirus COVID-19 Cytokines develop double-blind EudraCT feasible febrile Grifols groups IL-10 IL-1β IL-6 IL-8 Inflammation interleukin-6 intravenous moderate Mortality multicenter Necrosis patients patients receiving placebo patients with COVID-19 phase 3 trial Placebo placebo-controlled trial plasma primary endpoint pro-inflammatory progression Randomized randomized control trial randomized control trial. receive receptor reduce Safe Secondary endpoints severe ARDS severe coronavirus disease Support syndrome the placebo group therapeutic Tolerability Treatment treatment group Trial ventilator ventilator-free day was increased were assessed [DOI] 10.1016/j.medj.2022.03.001 PMC 바로가기 [Article Type] Clinical Trial
Supporting business educators and students against COVID-19 trauma using trauma-focused cognitive behavioral therapyRandomized Controlled Trial Published on 2022-04-082022-10-05 Journal: Medicine [Category] 임상, [키워드] adverse effect Anxiety arising assigned cognitive control groups Coping strategy coronavirus COVID-19 COVID-19 pandemic Depression distress Effect Factor Follow-up Gender indicated Intervention mental health mental health problem Nigeria no significant difference outbreak outcome participant Participants Post-traumatic stress disorder Psychological PTSD questionnaire Randomly reduced repeated measure Research significantly Study participants Support Supporting Symptom therapy trauma Treatment treatment group variance was used [DOI] 10.1097/MD.0000000000029133 PMC 바로가기 [Article Type] Randomized Controlled Trial
Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial)COVID-19 환자에서 회복기 혈장 요법의 효능: 무작위 대조 시험(COPLA-II 시험)Clinical Trial Published on 2022-04-062022-09-12 Journal: BMJ Open [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 1:1 48 hour adverse events allergic reaction Antibody titre Blood blood bank & Clinical improvement clinical outcomes collected conducted convalescent plasma Convalescent plasma therapy COVID-19 COVID-19 patient cytokine level D-dimer Efficacy Hospital admission hospitalisation in both group incidence initial IQR median median time Mortality no difference on mechanical ventilation outcome PaO participant Patient plasma proportion randomised randomised controlled trial reduction in SARS-CoV-2 antibody secondary severe COVID-19 patients study population the patient therapy TNF-α transfused Transfusion medicine Treatment treatment group Trial [DOI] 10.1136/bmjopen-2021-055189 PMC 바로가기 [Article Type] Clinical Trial
Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical TrialRandomized Controlled Trial Published on 2022-04-052022-10-05 Journal: JAMA [Category] COVID19(2023년), SARS, 변종, 임상, 진단, 치료제, [키워드] 1:1 24 hour absolute difference acute illness adjusted adjusted relative risk Adverse adverse event age all-cause hospitalization Brazil Canada clinical clinical trial collected conducted COVID-19 COVID-19 progression Critical death diarrhea Disease progression duration of follow-up Effect Efficacy end point evaluate event favor Follow-up high-risk patient Hospitalization increased risk infected with SARS-CoV-2 interim analysis intravenous intravenous dose Latinx management mechanical ventilation median age Mild Moderate COVID-19 neutralizing antibody outcome Patient patients randomized patients with COVID-19 Placebo Pneumonia Prevent Primary outcome progression proportion Randomized reduced requiring supplemental oxygen risk risk factor SARS-CoV-2 variant secondary outcome severe disease significantly Sotrovimab Spain statistically significant Support symptomatic tested the median those with comorbidity Treatment treatment group [DOI] 10.1001/jama.2022.2832 PMC 바로가기 [Article Type] Randomized Controlled Trial
Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in IndiaClinical Trial Published on 2022-04-022022-10-05 Journal: Lancet (London, England) [Category] COVID19(2023년), SARS, 임상, [키워드] 1:1 95% CI Administered adverse event Analysis assessment assigned baseline Biotechnology clinical clinical trial comorbid conditions conducted COVID-19 criteria Cutoff death Department DNA dose double-blind Efficacy efficacy analysis eligible enrolled Government of India Gujarat identify immunogenic India individual injection interim analysis investigators multicentre Occurrence Older outcome assessor participant per-protocol population Phase 3 phase 3 trial Placebo placebo group placebo-controlled placebo-controlled study Primary outcome randomisation randomised Randomly receive Registered registry reported Safe safety population SARS-CoV-2 SARS-CoV-2 vaccine screened symptomatic the placebo group Tolerability Treatment treatment group Trial Vaccine was done was used [DOI] 10.1016/S0140-6736(22)00151-9 PMC 바로가기 [Article Type] Clinical Trial
Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trialClinical Trial Published on 2022-04-012022-10-05 Journal: The Lancet. Haematology [Category] Fulltext, MERS, 임상, [키워드] 1:1 absence acute respiratory distress adjusted adjusted relative risk Administered adverse event age assigned average benefit Blood blood product Care caused characteristics of patient clearance Complication concealed COVID-19 pandemic Critical care deaths defined eligibility Follow-up identify Injury intention-to-treat population intravenous investigated involved IQR Lactate Liver function male median median age Mortality multicentre nine occurred Open-label outcome parallel group participant participants randomly assigned Patient phase 3 trial plasma Primary outcome pulse randomisation randomised Randomly receive receiving recruitment red blood cell reducing mortality Registered remains uncertain required Research Resuscitation risk Sample size Serious Adverse Events severity Shock Sodium chloride stratified syndrome Systolic blood pressure time tissue trauma Treatment treatment group Trial were assessed [DOI] 10.1016/S2352-3026(22)00040-0 PMC 바로가기 [Article Type] Clinical Trial